Thursday, January 26, 2012
Theravance to Report Fourth Quarter and Full Year 2011 Financial Results on February 9, 2012
Monday, January 9, 2012
GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily RelovairTM* in COPD and asthma
Friday, January 6, 2012
Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV® (telavancin) for Injection
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs. Learn How
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas. Learn How
We partner with leading pharmaceutical companies to accelerate development and commercialization of our product candidates. Learn How
Every day at Theravance, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines. Learn How
Theravance discovers, develops and brings important medicines to patients by: